Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute Inc (TOI) delivers community-focused cancer care through innovative treatment models and value-based services. This page serves as the definitive source for official company announcements, financial updates, and strategic developments.
Access real-time updates on TOI's clinical trial advancements, partnership agreements, and operational milestones. Investors will find earnings reports, leadership updates, and market-moving news consolidated for efficient analysis. Media professionals can track press releases detailing TOI's expansion of outpatient services and community health initiatives.
Key content categories include quarterly financial disclosures, research collaborations, care model innovations, and regulatory developments. All materials are sourced directly from TOI's corporate communications, ensuring accuracy and timeliness.
Bookmark this page for streamlined access to TOI's evolving story in oncology care. Check regularly for updates that matter to stakeholders monitoring the intersection of healthcare innovation and value-based treatment delivery.
The Oncology Institute (NASDAQ: TOI) has announced a strategic partnership with Doctors HealthCare Plans to enhance oncology care management in South Florida. TOI will provide delegated utilization management services and clinical advisory support for the Medicare Advantage plan's members.
Under this collaboration, TOI will manage oncology services using its clinical protocols, medical director oversight, and technology-enabled workflows. The partnership aims to support optimal oncology benefit design and evidence-based care pathways, building on TOI's successful track record of managing medical cost risk across multiple states.
The partnership focuses on ensuring patients receive appropriate care while improving outcomes and maintaining cost effectiveness in the healthcare system.
The Oncology Institute (NASDAQ: TOI) reported strong Q2 2025 financial results, with consolidated revenue reaching $119.8 million, up 21.5% year-over-year. The company's pharmacy business showed exceptional growth of over 40%, while adding 50,000 new capitated lives.
Key financial metrics include gross profit of $17.5 million (up 34.4%), net loss of $17.0 million, and Adjusted EBITDA of $(4.1) million. TOI reaffirmed its full-year 2025 guidance, expecting revenue between $460-480 million and targeting the higher end of this range. The company anticipates reaching Adjusted EBITDA positivity by the end of 2025.
Strategic developments include planned expansion in Florida markets and a new capitation relationship with Silver Summit Health Plan in Nevada. TOI also welcomed new executive appointments to strengthen its clinical and administrative leadership.
The Oncology Institute (NASDAQ: TOI), one of the largest value-based oncology groups in the US, announced significant leadership changes to its Board of Directors. Richard Barasch will retire as Chairman of the Board, effective August 12, 2025, with Anne McGeorge, current Board Member and Audit Committee Chair, succeeding him.
McGeorge brings over 35 years of healthcare experience, notably having grown Grant Thornton LLP's Global Health Care and Life Sciences Practice into a $250 million global business. She currently serves on multiple boards including Dianthus Therapeutics (NASDAQ: DNTH), Nimbus Therapeutics, and CitiusTech.
Under Barasch's leadership, TOI successfully became a publicly traded company and expanded its business model beyond California.
The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 13, 2025, after market close.
The company will host a conference call at 5:00 p.m. Eastern Time on the same day. Investors can join via phone (1-877-407-0789 for domestic, 1-201-689-8562 for international) or webcast through TOI's Investor Relations website. A replay will be available until August 20, 2025, using passcode 13754165.
The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, has appointed Kristin England as its new Chief Administrative Officer (CAO), effective July 7, 2025. In this newly created position, England will be responsible for overseeing Enterprise Central Business Operations and Technology Strategy across TOI's national operations.
England joins TOI with over 20 years of healthcare management experience, previously serving as a senior executive at McKesson's US Oncology Network, where she specialized in revenue cycle optimization and practice management systems improvement. CEO Daniel Virnich emphasized that England's appointment comes at a crucial time as TOI focuses on scaling its MSO model and strengthening its value-based care approach.
The Oncology Institute (NASDAQ: TOI) has announced a significant partnership with SilverSummit Healthplan, becoming the exclusive oncology provider for over 80,000 Medicaid patients in Nevada, effective July 1. This expansion marks an important step in TOI's mission to provide value-based cancer care to underserved communities.
The partnership will operate through three Nevada locations in Las Vegas, Henderson, and Spring Valley, offering comprehensive cancer care services to SilverSummit Healthplan members. This collaboration aligns with TOI's track record of serving Medicaid patients and SilverSummit's commitment to providing high-quality healthcare access to its members.
The Oncology Institute (NASDAQ: TOI) has appointed Dr. Jeffrey Langsam as its new enterprise Chief Clinical Officer (CCO), effective May 13th, 2025. In this role, Dr. Langsam will oversee therapeutics, including pathway and procurement decisions, utilization management, and MSO practice clinical engagement.
Dr. Langsam joins TOI from Cigna Healthcare, where he served as National Director of Oncology and Senior Medical Director in the Specialty Pharmacy Division. His previous experience includes roles as Regional Medical Director at Aetna and clinical faculty at the University of Connecticut, where he practiced as an oncologist.
The appointment comes as TOI experiences acceleration in new value-based partnerships and growth in its MSO model across the country.
The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, announced its participation in the upcoming B. Riley's 25th Annual Institutional Investor Conference. The event will take place on May 21st, 2025, in Marina Del Rey, CA. The company will be represented by CEO Dr. Daniel Virnich and CFO Rob Carter.
FAQ
What is the current stock price of The Oncology Institute (TOI)?
What is the market cap of The Oncology Institute (TOI)?
